Home > Analytics > TORRENT PHARMACEUTICALS

TORRENT PHARMACEUTICALS
Intrinsic Value | Fundamental Analysis

BOM : 500420     NSE : TORNTPHARM    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive]
Debt : High
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward
Pledged Shares : None or < 25%
Mar 18,2024
Price(EOD): ₹ 2,567.20
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 86,874.05 Cr
Value of ₹ 1 Lac invested in TORRENT PHARMACEUTICALS
on Mar 18,2019 (price: ₹ 924.60)

₹ 1 L

₹ 2.78 L

1W : -4% 1M : -2.8% 1Y : 70.3%
COMMUNITY POLL
for TORRENT PHARMACEUTICALS
Please provide your vote to see the results
TORRENT PHARMACEUTICALS is part of below Screeners ↓
Top Large Cap Stocks with Best Fundamentals
Best Quarterly Growth Large Cap Stocks
Industry Peers & Returns1W1M1Y
TORRENT PHARMACEUTICALS -4% -2.8% 70.3%
SUN PHARMACEUTICAL INDUSTRIES -0.8% 4% 61.6%
DIVIS LABORATORIES -2.1% -6% 26.4%
CIPLA 1.5% 3.3% 70.6%
DR REDDYS LABORATORIES 0.7% 0.4% 44.6%
ABBOTT INDIA 6% -3% 39.7%
ZYDUS LIFESCIENCES 0.3% 11.1% 109.1%
ALKEM LABORATORIES -1.5% -8.6% 63.1%
LUPIN -2% -0.5% 149.9%

FUNDAMENTAL ANALYSIS OF TORRENT PHARMACEUTICALS

 
Fundamentals Score
[ Q(TTM): Dec2023, Y: Mar2023
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]

Insights 💡 TORNTPHARM is one of the top 35% companies with good fundamentals ! Discover More →

VALUATION OF TORRENT PHARMACEUTICALS

 
Valuation Score
[As on : Mar 18,2024 ]

Ratio Consolidated
P/E
P/B
P/S
58.16
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1,494.00 Cr
[Latest Qtr - Dec2023 - Consolidated Results ]

14.02
P/B Calculated based on Book Value of Rs 6,198.07 Cr
[Latest Year - Mar2023 - Consolidated Results ]

8.3
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 10,474.00 Cr
[Latest Qtr - Dec2023 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 16% undervalued companies ! Discover More →

FAIR VALUE OF TORRENT PHARMACEUTICALS

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
126%
243%
193%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF TORRENT PHARMACEUTICALS



TORRENT PHARMACEUTICALS vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF TORRENT PHARMACEUTICALS

Year Debt/Equity ratio
Standalone Consolidated
2023
2022
2021
Avg_3yrs
0.71
0.53
0.73
0.66
0.85
0.68
0.83
0.79
[Last Annual Data : Mar2023]
Financial Ratios →

PLEDGED PROMOTER SHARES OF TORRENT PHARMACEUTICALS

Pledged Promoter Shares
0 %
As on : Dec2023

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF TORRENT PHARMACEUTICALS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
2.71%
5.33%
12.88%
14.77%
9.67%
20.03%
50.6%
51.71%
QtrlyTrend
8
Latest Qtr: Dec2023
Quarterly Result Analysis →


TORRENT PHARMACEUTICALS related INDICES

BSE Indices1W1M1Y
S&P BSE 100 LARGECAP TMC -1.6% 0.5% 32.4%
S&P BSE LARGE MIDCAP -1.9% -0.1% 35.5%
S&P BSE 200 -1.9% -0.1% 35.3%
S&P BSE 250 LARGEMIDCAP -2% -0.4% 35.3%
S&P BSE HEALTHCARE -2.1% -2.4% 59.2%
NSE Indices1W1M1Y
NIFTY100 LOW VOLATILITY 30 -1.5% 0.3% 39.6%
NIFTY 100 -1.6% 0.6% 32.6%
NIFTY ALPHA QTY LOW-VOLAT.30 -1.8% 1.2% 49.1%
NIFTY PHARMA -2% 1.3% 62.2%
NIFTY ALPHA LOW-VOLATILTY 30 -2% 0.9% 54.9%

You may also like the below Video Courses


FAQ about TORRENT PHARMACEUTICALS


Is TORRENT PHARMACEUTICALS good for long term investment?

As on Mar 18,2024, the Fundamentals of TORRENT PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of TORRENT PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is TORRENT PHARMACEUTICALS UnderValued or OverValued?

As on Mar 18,2024, TORRENT PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of TORRENT PHARMACEUTICALS ?

As on Mar 18,2024, the Intrinsic Value of TORRENT PHARMACEUTICALS is Rs. 875.46 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 1,134.80
Fair Value [Median EV / Sales Model] : Rs. 747.47
Fair Value [Median Price / Sales Model] : Rs. 875.46
Estimated Median Fair Value of TORRENT PHARMACEUTICALS : Rs. 875.46

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is TORRENT PHARMACEUTICALS trading at a Premium or Discount?

As on Mar 18,2024, TORRENT PHARMACEUTICALS is trading at a Premium of 193% based on the estimates of Median Intrinsic Value!